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ABSTRACT
yLuc7p is an essential subunit of the yeast U1
snRNP and contains two putative zinc fingers. Using
RNA–protein cross-linking and directed site-specific
proteolysis (DSSP), we have established that the
N-terminal zinc finger of yLuc7p contacts the
pre-mRNA in the 50 exon in a region close to
the cap. Modifying the pre-mRNA sequence in the
region contacted by yLuc7p affects splicing in a
yLuc7p-dependent manner indicating that yLuc7p
stabilizes U1 snRNP–pre-mRNA interaction, thus
reminding of the mode of action of another U1
snRNP component, Nam8p. Database searches
identified three putative human yLuc7p homologs
(hLuc7A, hLuc7B1 and hLuc7B2). These proteins
have an extended C-terminal tail rich in RS and RE
residues, a feature characteristic of splicing factors.
Consistent with a role in pre-mRNA splicing, hLuc7A
localizes in the nucleus and antibodies raised
against hLuc7A specifically co-precipitate U1
snRNA from human cell extracts. Interestingly,
hLuc7A overexpression affects splicing of a reporter
in vivo. Taken together, our data suggest that
the formation of a wide network of protein–RNA
interactions around the 50 splice site by U1 snRNP-
associated factors contributes to alternative
splicing regulation.
INTRODUCTION
Splicing of most polII transcripts is required prior to their
export out of the nucleus (1). The spliceosome is the
macromolecular complex responsible for this intricate
process. Early spliceosome assembly events are target
of regulatory factors that alter splice site choice and/
or modulate splicing activity, constituting a widespread
mechanism of gene expression regulation (2).
Interestingly, processes as diverse as meiosis in yeast,
dosage compensation in fruit ﬂies or programmed cell
death in humans are regulated in this manner (3–5).
Spliceosome assembly in vitro is initiated by formation
of stable complexes containing U1 snRNP, pre-mRNA
and non-snRNP factors (6). In yeast, the earliest known
splicing complexes are called commitment complexes
because their formation targets the pre-mRNA substrate
to the splicing pathway (7). The mammalian E complex
is the counterpart of the yeast commitment complexes
(8). During the formation of commitment complexes, U1
snRNA base pairs with the intron and exon sequences
ﬂanking the 50 splice site (9–11), whereas the cap-binding
complex (CBC) binds to the pre-mRNA cap (12).
In addition, several protein components of the U1
snRNP make contacts with the pre-mRNA (13,14).
These protein–RNA contacts stabilize pre-mRNA–U1
snRNP interaction and aﬀect 50 splice site selection (13).
Like its metazoan counterparts, the yeast U1 snRNP
contains two classes of proteins: the Sm proteins shared
with the U2, U4 and U5 snRNPs and the U1 snRNP-
speciﬁc proteins (15,16). Interestingly, homologs of
all three mammalian U1 snRNP-speciﬁc proteins (U1-A,
U1-C and U1-70K) can be found in the yeast complex
(Mud1p, yU1-C and Snp1p, respectively). However, the
yeast U1 snRNP contains in addition seven speciﬁc
proteins (Snu71p, Snu65p, Snu56p, Prp39p, Prp40p,
Nam8p and yLuc7p) (15,17,18). Among these proteins,
only for Nam8p has been described a mammalian
homolog, the apoptotic factor TIA-1 (4,19).
We identiﬁed yLuc7p as component of the U1 snRNP
by means of biochemical puriﬁcation (referred to as
Snu30p in our previous study) (18) and through a genetic
screen causing synthetic lethality with CBC (17). Analysis
of yLuc7p mutants revealed that the composition of yeast
U1 snRNP was altered in these strains and that the
corresponding extracts were unable to support any of
the deﬁned steps of splicing unless supplemented with
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of introns with non-consensus 50 splice site or branchpoint
sequences was defective in yLuc7p mutant strains. For
reporters containing two competing 50 splice sites, a loss of
eﬃcient splicing of the cap proximal splice site was
observed in yLuc7p-deﬁcient cells, analogous to the defect
seen in strains lacking CBC. These results lead Fortes
et al. (17) to suggest that the loss of yLuc7p disrupts
a U1 snRNP–CBC interaction normally contributing
to 5’ splice site recognition.
Using a combination of RNA–protein cross-linking,
and a strategy we called Directed Site-Speciﬁc Proteolysis
(DSSP), we have now shown that yLuc7p contacts
speciﬁcally exon 1 of the pre-mRNA through the ﬁrst
of its two zinc ﬁnger motifs. Modiﬁcation of the RNA
sequence contacted by yLuc7p aﬀects the pre-mRNA
splicing eﬃciency in a yLuc7p-dependent manner. Our
data suggest that interaction of yLuc7p with the upstream
exon stabilizes the pre-mRNA–U1 snRNP interaction.
This is reminiscent of the mode of action of Nam8p, which
facilitates intron recognition by binding to intron
sequences following the 50 splice site (13). To assess
whether the function of yLuc7p in splice site selection is
conserved, we identiﬁed putative human homologs and
cloned cDNAs encoding two of them (hLuc7A and
hLuc7B2, respectively). Both proteins have RE and RS
repeats characteristic of splicing factors. In addition, they
have two zinc ﬁnger motifs similar to those present
in yLuc7p and characteristic of RNA-binding proteins.
By using antibodies raised against hLuc7A we show
that this protein localizes in the nucleus of HeLa cells.
Interestingly, these antibodies speciﬁcally precipitate U1
snRNA from HeLa extracts. Furthermore, overexpression
of hLuc7A in HeLa cells aﬀects splice site selection of an
adenovirus E1A reporter, directing splicing selection
towards the most 50 distal site. Our results demonstrate
that hLuc7A is a new U1 snRNP-associated splicing
factor. In addition, our data support the formation of
a wide network of protein–RNA interactions around the
50 splice site by U1 snRNP associated-factors. This
network allows for modulated 50 splice recognition and
contributes thereby to alternative splicing regulation.
MATERIALS AND METHODS
Strains and plasmids
All yeast strains derive from the wild-type MGD353-13D
(9). BSY885 (yLuc7p-protA) and BSY761(Nam8p-TAP)
were constructed following standard methodology (20,21).
BSY747(yLuc7p-TAP) and BSY593(Nam8p-protA) have
been previously described (13,18). The yLuc7p-HA-TEV-
protA fusion inserted in a centromeric LEU2 plasmid
was introduced by plasmid shuﬄing in a strain carrying
a disrupted chromosomal copy of LUC7 to give strain
BSY1069. An isogenic wild-type strain expressing the
yLuc7p-protA fusion was constructed in parallel and
named BSY1067. The deletion of the ﬁrst zinc ﬁnger of
yLuc7p (fusion yLuc7p-ZF-protA) was built following
the same strategy, yielding strain BSY1077.
All the RP51A derivatives used in cross-linking
reactions were synthesized with a speciﬁc activity of
2 10
7Ci/mol as previously described (7). The constructs
WT-B and 50SSmut correspond to the plasmids pBS195
and pBS196, respectively (13,22) and were linearized
with EcoRV prior to transcription. In order to obtain
constructs Ex50U (plasmid pBS1983), Ex30U (pBS1982)
and IntU (pBS1985), the sequence including from the
T7 promoter to the EcoRV site from plasmid pBS195 was
cloned by PCR between the EcoRI and XbaI sites of
pUC19. The EcoRV site present in pBS195 was sub-
stituted by a PvuII site since this site lacks Ts upstream the
site of cleavage and therefore no Us are incorporated
upon transcription. These constructs were linearized prior
to transcription with PvuII.
To analyze commitment complex assembled in mRNAs
containing Ex50U, Ex30U and IntU sequences, we cloned
by PCR the sequence between the EcoRV and the DdeI
sites from plasmid pBS195 downstream of the XbaI site
of each construct.
Plasmid pBS983 (23) was used to build the reporters
used in splicing assays. It contains a synthetic intron
inserted upstream of the lacZ coding sequence designed to
include unique restriction sites in the intron and ﬂanking
exons. Sequences A, G and H (Figure 4A) were generated
by PCR and introduced between the BamHI and KpnI
sites of pBS983. Sequence H can potentially form a
hairpin structure with G= 8.2kcal/mol at 258C.
Duplications were obtained by cloning the XhoI–SacI
fragment from each construct in the SalI–SacI sites of the
same plasmids (13,22,24). Constructs AA, AG, AH, GA,
GG, GH, HA, HG and HH correspond to the plasmids
pOP708 to pOP716.
The sequence of hLuc7B2 is deduced from recon-
structed cDNA sequence derived from the IMAGE clones
156683 and 897347. A full-length coding sequence
was recreated by combining these two clones to give
pBS1903. The sequence coding for hLuc7A was obtained
by sequencing IMAGE clone 198596 and sequencing a 30
RACE fragment to give plasmid pBS2101.
Plasmids overexpressing SF2 and hnRNPA1 in pCGT7
(tagged with a T7 epitope) and the expression reporter
for adenovirus E1A were gifts from J. Caceres (25). To
overexpress hLuc7A in eukaryotic cells, the hLuc7A ORF
was subcloned between the BamHI and XbaI sites of
pCGT7. All the constructs were conﬁrmed by sequencing.
Splicinganalysis, cross-linking and DSSP
b-Galactosidase assays were performed twice independently
and in duplicate. Variation between duplicate samples
was at most 20%. Standard deviation is represented.
Extract preparation, commitment complex formation
and cross-linking analysis were performed as described
(13). All pre-mRNAs used in cross-linking reactions
were internally labeled with aP
32-UTP, and 4-thio-UTP
substituted for cold UTP. (13). Wash buﬀer in immuno-
precipitations was IPP150 (10mM Tris–Cl pH8.0,
150mM NaCl, 0.1% NP-40). For TEV digestion, after
immunoprecipitation the beads were sedimented in a
picofuge and 40ml of TEV cleavage buﬀer (IPP150 with
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Subsequently, samples were split in two and 1ml of TEV
enzyme (Gibco) was added to one of them. Samples were
incubated 30 min at 378C. Ten microliters of 3  SDS
loading buﬀer was added directly after cleavage and
proteins were analyzed by SDS–PAGE.
In the DSSP reactions, commitment complexes were
assembled using extracts derived from the yLuc7p–
HA-TEV–protA strain and from the parental yLuc7p–
protA strain. Samples were UV irradiated, treated with
RNaseT1, immunoprecipitated with IgG-coupled beads,
and split in two. One half was treated with TEV protease
while the other half was mock-treated. Subsequently,
proteins were analyzed by SDS–PAGE.
Antibody production andwestern blot
Fragments coding for most of the hLuc7A protein, the
N-terminal part containing the region of homology with
yLuc7p, or part of the C-terminal extension containing the
RS and RE repeats, were inserted in the pGEX2T0-6
plasmid (gift from V. Baldin) yielding plasmids pBS1905,
pBS1907 and pBS1909, respectively. All three constructs
were expressed in Escherichia coli codon plus RIL cells
(Stratagene). Rabbits (New Zealand White females) were
immunized following standard procedures.
Western blot to detect protein A tagged proteins was
performed with peroxidase-conjugated antiperoxidase
antibody (Sigma). Western blot anti-hLuc7A was per-
formed with antibody 0J38 (polyclonal against the
N-terminal part of hLuc7p) diluted at 1:1000. SF2,
hnRNPA1 and hLuc7A were detected in western blots
with speciﬁc antibodies against the T7 epitope tag
(Chemicon International) at 1:1000 dilution.
Immunoprecipitation ofHeLa nuclear extracts
HeLa cell nuclear extracts were prepared as described (26).
Fifty microlitres of beads were washed three times in
IPP150 and incubated with 100ml of serum (0J38 for
N-terminal, 0410 for C-terminal) and 300ml of IPP150 for
2h at 48C. The volume equivalent to 10ml of beads was
used for each immunoprecipitation experiment. The beads
were sedimented in a picofuge and 75ml of IPP150 plus
25ml of nuclear extract were added. After 2h at 48C, the
beads were extensively washed with IPP150. RNA was
recovered and analyzed by primer extension using primers
speciﬁc for U1 snRNA (CTGGGAAAACCACCTTCG
TGATC) and U2 snRNA (AGGACGTATCAGATAT
TAAACTG).
Immunolocalization
HeLa cells grown to 70% conﬂuence in DMEM medium
supplemented with 10% fetal calf serum were transferred
to coverslips and incubated overnight to allow for
attachment. Cells were washed with PBS, ﬁxed with 2%
formaldehyde in PBS for 5 min at 378C and permeabilized
by incubation in 0.1% NP-40 in PBS for 10 min at 378C.
After washing with PBS, cells were incubated in presence
of hLuc7A antibody 03J0 (raised against the N-terminal
fragment of hLuc7A) at 1:5000 dilution and anti-tubulin
(T9026, Sigma) at 1:1000 dilution for 2h at RT. Cells were
extensively washed with PBS and incubated with the
secondary antibody (anti-rabbit Alexa 488 and anti-mouse
Alexa 568, both from Molecular Probes) at 1:100 dilution
for 1h at RT. Cells were extensively washed with PBS,
stained with DAPI (at 5mg/ml) and coverslips were
mounted for observation under a confocal microscope
(Axioplan, Zeiss) equipped with a digital color video
camera (Leica, Model LEI-750TD).
In vivosplicing assays
HeLa cells were grown in 60mm Ø plates to 50%
conﬂuence in DMEM medium supplemented with 10%
fetal calf serum. Cells were transfected with eﬀectine
reagent (Qiagen) using 300ng of adenovirus E1A reporter,
170ng of SF2 expression plasmid and 90 or 130ng of
hnRNPA1 or hLuc7A expression plasmids. pBluescript
(Stratagene) was added to normalize the amount of
DNA. Forty-eight hours post-transfection RNA was
puriﬁed (Trizol, Gibco) and RT–PCR was performed as
described (27).
RESULTS
yLuc7p specifically cross-links the pre-mRNA
yLuc7p has two zinc ﬁnger motifs of the types CCCH and
CCHH, respectively. These motifs have been shown to act
in other proteins as RNA-binding modules. Thus we
tested whether yLuc7p binds the pre-mRNA in commit-
ment complexes. We synthesized P
32-internally-labeled
WT-B pre-mRNA, a derivative of the RP51A intron (22)
with 4-thio-U substituted for normal U. This RNA was
used to assemble commitment complexes in an extract
prepared from a yeast strain expressing yLuc7p fused at
its C-terminus with the Staphyloccocus aureus protein
A (yLuc7p-protA, this modiﬁcation has no phenotypic
consequence). Subsequently, the reactions were UV
irradiated, treated with RNase T1 and immunoprecipi-
tated by using IgG-coupled beads. Cross-linked proteins
present in the precipitate were analyzed by SDS–PAGE
and identiﬁed by autoradiography. As a positive control
we used Nam8p-protA, a protein known to contact the
pre-mRNA in the intron downstream from the 50 splice
site (13). Nam8p–protA cross-linked to the functional
WT-B pre-mRNA (Figure 1, lane 1). The corresponding
signal was strongly reduced when we used the 50SSmut
pre-mRNA (lane 2), which contains a mutation in the
50 splice site sequence (GUAUaU instead of GUAUGU)
known to impair commitment complex formation (9).
Figure 1, lane 3, shows the pattern of cross-linking
obtained when an extract from a yLuc7p–protA tagged
strain was used in commitment complex formation
with the WT-B pre-mRNA. A protein migrating with
the expected size of yLuc7p–protA cross-links to the
pre-mRNA. This band was only detected when 4-thio-U
substituted RNA was used for cross-linking (data not
shown). Further experiments conﬁrmed the identity of this
protein as yLuc7p–protA (data not shown). The cross-
linking signal is reduced to background level when the
50SSmut substrate is used (Figure 1, lane 4) suggesting that
it is meaningful in terms of splicing. These results indicate
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complex formation. Similar results have been reported
for other yeast U1 snRNP proteins such as Nam8p.
Strikingly, yLuc7p had not been previously identiﬁed in
a general analysis as a subunit of U1 snRNP contacting
the pre-mRNA (14).
yLuc7p contactsthe pre-mRNA in the50 exon
To determine the region of the pre-mRNA cross-linking
to yLuc7p, we used a truncated version of the WT-B
pre-mRNA (22) (Figure 2A). The pre-mRNA branchpoint
region and downstream sequences were found to be
dispensable for this reaction, indicating that yLuc7p
contacts the pre-mRNA during formation of the ﬁrst
commitment complex (CC1) in the vicinity of the 50 splice
site (data not shown).
To narrow down the pre-mRNA region cross-linking
to yLuc7p we used derivatives of the WT-B carrying
substitutions such that non-essential U residues were
replaced by A residues in speciﬁc regions of the
pre-mRNA (14) Three substrates covering the exon 1
(the 50 exon) and the intron upstream of the branchpoint
were used for these experiments (Figure 2A). Each
substrate contained essential U residues in the 50 splice
site (GUAUGU). In addition, Ex50U contained U
residues in the 50 half of exon 1 (nucleotides  42 to
 19, where  1 is the nucleotide adjacent to the 50 splice
site, Figure 2A), Ex30U contained U residues in the 30 half
of exon 1 (nucleotides  18 to  1) and IntU contained U
residues in the intron region (nucleotides +1 to +66)
(Figure 2A). Because 4-thio-U residues are essential for
the detection of yLuc7p cross-linking to the pre-mRNA,
appearance of a cross-linked species with one of these
substrates would identify the region of contact between
yLuc7p and the pre-mRNA. Cross-linking to all three
substrates would indicate that yLuc7p contacts the pre-
mRNA at the 50 splice site itself. Control experiments
demonstrated that these substrates, in the context of wild
type, branchpoint and 30splice site sequences (Materials
and Methods section) formed commitment complexes
with the same eﬃciency (Supplementary Figure 1).
Commitment complexes were assembled in extracts con-
taining yLuc7p–ProtA, yLuc7p–TAP and Nam8p–TAP
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49 
80
Extract
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Figure 1. yLuc7p cross-links the pre-mRNA. Yeast extracts from
Nam8p–protA (lanes 1 and 2) or yLuc7p–protA (lanes 3 and 4) tagged
strains were incubated with WT-B (lanes 1 and 3) or 50SSmut (lanes 2
and 4) pre-mRNAs. After cross-linking and immunoprecipitation,
proteins were separated by SDS–PAGE.
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Figure 2. yLuc7p cross-links the WT-B pre-mRNA in a region close to
the 5’cap. (A) Substrates used in cross-linking. WT-B full length, or
truncated at the EcoRV site, were internally labeled with aP
32-UTP and
4-ThioU all over their sequence. Ex50U contains 4-ThioU only in the
50 half of exon 1 (nucleotides  42 to  19, where  1 represents the
residue adjacent to the 50 splice site) and in the 50 splice site sequence
(GUAUGU, necessary to form commitment complexes). Ex30U
contains 4-ThioU only in the 30 half of exon 1 (nucleotides  18
to  1) and also in the 50 splice site sequence. IntU contains 4-ThioU
only in the intron (nucleotides +1 to +66). (B) Cross-linking to
diﬀerent substrates. Nam8p–TAP (lanes 1 and 2), yLuc7p–protA
(lanes 5 and 6) and yLuc7p–TAP (lanes 3, 4, 7 and 8) tagged extracts
were incubated with IntU (lanes 1, 2 and 8), Ex50U (lanes 3 to 6) or
Ex30U (lane 7) P
32-labeled pre-mRNAs, cross-linked, RNaseT1 treated
and immunoprecipitated. Proteins were separated by SDS–PAGE.
Asterisks denote unspeciﬁc protein cross-linking. For unknown reasons,
the cross-linking signal observed with yLuc7p–protA was weaker than
yLuc7p–TAP in this experiment.
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TAP tag) (18) and cross-linking reactions were carried out
as before. yLuc7p–TAP cross-linked speciﬁcally to the
Ex50U substrate but not to the Ex30U or IntU pre-mRNA
(Figure 2B, compare lanes 3, 7 and 8). Consistently,
yLuc7p-ProtA also cross-linked to the Ex50U substrate
(Figure 2B, lanes 5 and 6). In contrast, Nam8p–TAP was
only cross-linked to the IntU substrate (Figure 2B, lanes 1
and 2), which was consistent with previous analyses (13),
and demonstrated that this substrate was competent
for cross-linking.
In order to conﬁrm the identity of the cross-linked
protein in the bands detected, half of the pellets in each
cross-linking reaction were cleaved with the TEV protease.
This enzyme speciﬁcally cleaves the TAP tag (18) releasing
a  15-kDa ProtA fragment. As expected, the cross-linked
species detected when we used Nam8p–TAP or yLuc7p–
TAP tagged extracts were cleaved with the TEV protease
(compare lanes 1 with 2, and 3 with 4). However, there
was no diﬀerence in mobility between TEV-treated and
untreated samples when extracts from yLuc7p–protA were
used (lanes 5 and 6), indicating that the cleavage observed
was speciﬁc for the TAP tag and there are no other
TEV sites within yLuc7p. Similarly, non-speciﬁc back-
ground bands were not aﬀected by TEV protease
treatment (Figure 2B, bands indicated with an asterisk).
yLuc7p–TAP, yLuc7p–TAP cleaved by TEV protease,
and yLuc7p–ProtA migrated at diﬀerent positions, con-
sistent with their predicted relative molecular weights
(compare lanes 3, 4 and 5). These data conﬁrm unequiv-
ocally the identiﬁcation of the cross-linked species as
yLuc7p. Moreover, this experiment demonstrates that,
during commitment complex formation, yLuc7p contacts
the 50 half of exon 1 in the WT-B pre-mRNA, a region
that in this construct is within 23nt from the 50 cap.
yLuc7pbinds the pre-mRNA withits first zinc finger
Zinc ﬁnger motifs have been shown to act as DNA or
RNA-binding modules (28). Since yLuc7p has two zinc
ﬁnger motifs, we wanted to know whether yLuc7p
contacts the pre-mRNA through any of its zinc ﬁnger
motifs. For this purpose, we adapted a strategy originally
described for topological studies of membrane proteins
(29). We reasoned that insertion of a TEV protease
cleavage site in a non-conserved loop at the surface of
the yLuc7p protein would result in the synthesis of a
functional protein. This would then allow DSSP of this
polypeptide after cross-linking and identiﬁcation of the
peptide covalently linked to the radiolabeled RNA
fragment. We ﬁrst inserted the sequence coding for an
HA epitope tag and a TEV site in regions predicted from
phylogenetic comparison to be in a variable loop exposed
on the surface of the yLuc7p protein and located between
the two putative zinc ﬁngers. These fusions were
engineered in the context of a yLuc7p–ProtA fusion and
next tested to determine whether they were functional
and if they fully complemented a yLuc7p deletion. One
such fusion, named here yLuc7p–HA-TEV–protA,
was selected for further studies (Figure 3A). Western
blot of extracts obtained from this strain showed that
yLuc7p–HA-TEV–protA is stable in yeast cells
(Figure 3B, lane 2). Commitment complex reactions
were assembled using extracts derived from this strain
and from the parental yLuc7p–protA strain. Samples were
UV irradiated, immunoprecipitated with IgG-coupled
beads and split in two. One half was treated with TEV
protease while the other half was mock-treated. Proteins
were analyzed by SDS–PAGE. Both yLuc7p–protA and
yLuc7p–HA-TEV–protA cross-linked eﬃciently to pre-
mRNA (Figure 3C, lanes 5 and 6). No eﬀect was observed
after TEV treatment of the yLuc7p–protA sample
(Figure 3C, compare lanes 5 and 9). However, after
TEV treatment, yLuc7p–HA-TEV–protA releases a frag-
ment which is cross-linked to the pre-mRNA and has a
mobility of  18 kDa, corresponding to the size of the
N-terminal half of yLuc7p plus the HA tag (Figure 3C,
lane 10). Reproducible cross-linking to the C-terminal half
(approximate MW 30kDa) was not observed even though
a weak and diﬀuse band with slower mobility (possibly a
degradation product, shown in Figure 3 with an asterisk)
was sometimes detected. This result demonstrates that the
N-terminal part of yLuc7p cross-links to the pre-mRNA.
Although our results suggest that in these conditions no
interaction occurs through the C-terminal half of yLuc7p,
due to the presence of the spurious band migrating close
to 30kDa in some of our experiments, we cannot exclude
the possibility that the second zinc ﬁnger may bind
cooperatively aiding in the U1snRNP–pre-mRNA
interaction.
To further demonstrate that yLuc7p makes contacts
with the pre-mRNA through its ﬁrst zinc ﬁnger we
generated a deletion mutant of yLuc7p HA-TEV–protA
(named yLuc7p-ZF), which lacked its ﬁrst zinc ﬁnger
(Figure 3A). Cells expressing this protein as the sole
source of yLuc7p were viable, indicating the ﬁrst zinc
ﬁnger is not essential. Western blot experiments showed
that the protein lacking the ﬁrst zinc ﬁnger was stable in
yeast extracts (Figure 3B, lane 3). Interestingly, cross-
linking of the pre-mRNA to this protein was completely
abolished (Figure 3C, lanes 8 and 12). This lack of cross-
linking was not due to problems with that particular
sample since all samples cross-linked with similar eﬃ-
ciency as shown before immunoprecipitation (Figure 3C,
lanes 1–4). Altogether these results demonstrate that
yLuc7p makes contacts with the pre-mRNA through its
ﬁrst zinc ﬁnger.
The sequence of thepre-mRNA region where yLuc7p
binding affects the efficiency of splicing in a
yLuc7p-dependent way
Non-conserved sequences surrounding the 50 splice site
have been shown to be very important for eﬃcient splicing
(13). Given that yLuc7p makes contacts with the
pre-mRNA in a non-conserved region, we wanted to
know whether the sequence in that region aﬀected splicing
eﬃciency and whether yLuc7p was involved in this
process. For this purpose we turned to a sensitive assay
based on the alternative choice between two 50 splice sites
competing for a single 30 splice site (Figure 4A) (10,13,24).
The reporters used in this experiment had two duplicated
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to  35, Figure 4A) we introduced three diﬀerent
sequences: a sequence rich in Gs (G sequence), a sequence
that could potentially form a hairpin, (H sequence) and
a sequence with high content in As (A sequence). The
resulting reporters were named using a two-letter code,
where the ﬁrst letter represents the sequence preceding
(nucleotides  35 to  15, where  1 is the last nucleotide
of exon 1, Figure 4A) the upstream 50 splice site, and the
second letter represents the sequence preceding the
downstream 50 splice site (Figure 4A). According to this
nomenclature the construct named GH has a G-rich
sequence preceding the upstream 50 splice site and a
potential hairpin sequence preceding the downstream
A
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Figure 3. yLuc7p cross-links the pre-mRNA through its ﬁrst zinc ﬁnger. (A) Scheme representing the structure of yLuc7p–HA-TEV–protA.
(B) Western blot performed to detect protein A tagged proteins. (C) Extracts from yeast strains harboring yLuc7p–protA (lanes 1, 3, 5, 7, 9 and 11),
yLuc7p–HA-TEV-protA (lanes 2, 6 and 10) or yLuc7p–ZF (lanes 4, 8 and 12) were incubated with WT-B pre-mRNA. After cross-linking, samples
were treated with RNaseT1 and immunoprecipitated with IgG-coupled beads. TEV digestion was performed in samples 9–12. Lanes 1–4, no
immunoprecipitation. The position of yLuc7p–protA and its N-terminal half are indicated. The intense band above 172kDa is a non-speciﬁc cross-
linking product. The band marked with an asterisk migrating above 30kDa does not appear reproducibly in all experiments.
Nucleic Acids Research, 2007, Vol. 35, No. 17 587950 splice site (Figure 4A). These constructs were intro-
duced into isogenic yLuc7p–protA and yLuc7p–ZF
strains. Splicing eﬃciency was then examined by analyzing
b-galactosidase activity that reports usage of the upstream
versus the downstream 50 splice site (10,13,24). As shown
in Figure 4B, changing the sequence of the pre-mRNA
had important eﬀects in the eﬃciency of splicing. The
G-rich sequence was preferred over the A-rich sequence
(10-fold diﬀerence, Figure 4B, compare lanes 9 to 11 and
15 to 17, note the logarithmic scale), and the potential
hairpin H-sequence had an intermediate eﬀect (compare,
for example, lanes 7, 9 and 11). These eﬀects are lost in the
yLuc7p–ZF background (Figure 4B, compare odd with
even lanes for each construct) indicating that activation
was mediated, at least to a signiﬁcant extent, through the
ﬁrst zinc ﬁnger of yLuc7p. We conclude that the non-
conserved sequence contacted by yLuc7p has an eﬀect in
splicing eﬃciency and that yLuc7p, through interaction
with its ﬁrst zinc ﬁnger, can modulate this eﬀect. Although
these results suggest that the primary factor determining
splice site selection in this context is yLuc7p, we cannot
exclude contribution of yLuc7p-independent eﬀects to the
observed splicing phenotype. Thus it is possible that
additional factors, by contacting the pre-mRNA in the
same region, could act together with Luc7p to modulate
splice site selection.
Twoproteins withextended sequence homologyto yLuc7p
are expressed inhuman cell lines
Database searches revealed expressed sequence tags
(ESTs) corresponding to three human proteins sharing
extended homology with yLuc7p (hLuc7A, hLuc7B1 and
hLuc7B2) (17). We cloned cDNAs for two of them,
hLuc7B2 and hLuc7A (Figure 5A). Both proteins have
two zinc ﬁnger motifs similar to the yeast protein.
Interestingly, the human proteins have extended
C-terminal domains rich in arginine, serine and glutamate
(and to a lesser extent lysine and aspartate) as indepen-
dently noted by others (30,31). Similar repeats are present
in a number of known splicing factors, the SR proteins
(32). Computer analysis using the cDNA sequence of
hLuc7A also revealed several isoforms resulting from
alternative splicing (data not shown) (Figure 5B).
N-terminal or C-terminal fragments of hLuc7A were
expressed in E. coli and used to raise rabbit polyclonal
antibodies. Antibodies against hLuc7A recognized a
single band in HeLa nuclear extracts migrating in SDS
polyacrylamide gels with an apparent MW of 58kDa
(Figure 5C). The same protein was detected in extracts
from a wide variety of human cell lines (lanes 1–5 and data
not shown). In addition, faint signals corresponding
to shorter proteins were detected with some cells
(e.g. lanes 1 and 3). These smaller products may
correspond to a splice variant or to post-translational
modiﬁcation (i.e. phosphorylation) or weakly cross-
reacting polypeptides expressed from the related hLuc7A
and/or hLuc7B2 genes. Antibodies against hLuc7A also
cross-reacted with a protein present in Xenopus egg
extracts with similar mobility than hLuc7A (Figure 5C,
lane 7), and weakly with a protein present in Drosophila S2
cell line extracts which has higher mobility. These results
suggest that hLuc7A is expressed in diﬀerent tissues and
that it is present in metazoans from ﬂies to humans.
hLuc7A is anuclear protein
In order to know the subcellular localization of hLuc7A
we used the antibodies raised against the N-terminal part
of hLuc7A in immunolocalization studies. Figure 6 shows
that anti-hLuc7A antibodies recognize a protein that
co-localizes in HeLa cells with the DAPI signal for DNA.
The hLuc7A signal does not overlap with the cytoplasm
stained with an antibody speciﬁcally recognizing tubulin.
Interestingly, the hLuc7A signal is not uniform in the
nucleus. This is consistent with the speckled staining
detected for other splicing factors in mammalian cells (33).
This result demonstrates that hLuc7A is a nuclear protein
consistent with a role in pre-mRNA splicing.
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Figure 4. yLuc7p aﬀects 50 splice site selection. (A) Representation of
the reporter constructs used to analyze splicing. b-Galactosidase
activity reports splicing from the upstream versus the downstream
50 splice. (B) Plasmids carrying A, G and H sequences in all possible
combinations in both splice sites were transformed in the yLuc7p–
protA (white bars) or yLuc7p–ZF (black bars) strains.
5880 Nucleic Acids Research, 2007, Vol. 35, No. 17xLuc7A   -------MSAQAQMRALLDQLMGTSR-----DGDETRQRIKFTDDRVCKSHLLDCCPHDILAGTRMDLGECTKNHDLALRADYEIASKERDLF--FELDAMDHLESFIAECDRRTELAKK 106
xLuc7B   -------MSAQAQMRAMLDQLMGTAR-----DGDETRQRVKFTDDRVCKSHLLDCCPHDILAGTRMDLGECTKIHDLALRADYEIDRKERDLF--FELDAMDHLESFIAECDRRTELAKK 106
hLuc7B1  -------MSAQAQMRALLDQLMGTAR-----DGDETRQRVKFTDDRVCKSHLLDCCPHDILAGTRMDLGECTKIHDLALRADYEIASKERDLF--FELDAMDHLESFIAECDRRTELAKK 106
hLuc7B2  -------MSAQAQMRAMLDQLMGTSR-----DGDTTRQRIKFSDDRVCKSHLLNCCPHDVLSGTRMDLGECLKVHDLALRADYEIASKEQDFF--FELDAMDHLQSFIADCDRRTEVAKK 106
xLuc7C   -------MSAQAQMRALLDQLMGTSR-----DGDSTRQRIKFNDERVCKSHLLNCCPHDILLGTRMDLGECLKVHDLALRADYEIASKQQDFF--FELDAMDHLQSFIADCDRRTEIAKK 106
dLuc7    MSAPSNKMSATDQMRAMLDQLMGTTR-----NGDE--RQLKFSDPRVCKSFLLDCCPHDILASTRMDLGECPKVHDLAFRADYESAAKTRDYY--YDIEAMEHLQAFIADCDRRTDSAKQ 111
hLuc7A   ----------MISAAQLLDELMGRDRNL---APDEKRSNVRWDHESVCKYYLCGFCPAELFTNTRSDLGPCEKIHDENLRKQYEKSSRFMKVG--YERDFLRYLQSLLAEVERRIRRGHA 105
yLuc7p   ---MSTMSTPAAEQRKLVEQLMGRDFSFRHNRYSHQKRDLGLHDPKICKSYLVGECPYDLFQGTKQSLGKCPQMHLTKHKIQYEREVKQGKTFPEFEREYLAILSRFVNECNGQISVALQ 117
.   ::::***          .     :   .  :** .* . ** :: : .*: .*** : *    : :**   :  .    :: : :  *. :: : : :   . 
xLuc7A   RLAETQEEISAEVS----VKAEKVHELNEEIGKLLAKAEQLGAEGNVDEAQKILMEMENVKGRKREAEEEYRNSMPAS-SFQQQKLRVCEVCSAYLGLHDNDRRLADHFGGKLHLGFILI 221
xLuc7B   RLAETQEEISAEVS----VKAEKVHELNEEIGKLLAKAEQLGAEGNVDEAQKILMEMEKVKGRKREAEDEYRNSMPAS-SFQQQKLRVCEVCSAYLGLHDNDRRLADHFGGKLHLGFILI 221
hLuc7B1  RLAETQEEISAEVS----AKAEKVHELNEEIGKLLAKAEQLGAEGNVDESQKILMEVEKVRAKKKEAEEEYRNSMPAS-SFQQQKLRVCEVCSAYLGLHDNDRRLADHFGGKLHLGFIQI 221
hLuc7B2  RLAETQEEISAEVA----AKAERVHELNEEIGKLLAKVEQLGAEGNVEESQKVMDEVEKARAKKREAEEVYRNSMPAS-SFQQQKLRVCEVCSAYLGLHDNDRRLADHFGGKLHLGFIEI 221
xLuc7C   RLADTQEEISAEVA----VKAEKVHELNEEIGKLLAKAEQLGAEGNVEESQKVMDEVEKTRVRKREAEDIYRNSMPAS-SFQQQKLRVCEVCSAYLGLHDNDRRLADHFGGKLHLGFIEI 221
dLuc7    RLKETQEELTAEVA----EKANAVHGLAEEIGKKLAKAEALGEAGEVEDSMELMKEIEELRAKKIKAEHEYRTSMPAS-TYQQQKLRVCEVCSAYLGIHDNDIRLADHFGGKLHLGFLTI 226
hLuc7A   RLALSQNQQSSGAAGPTGKNEEKIQVLTDKIDVLLQQIEELGSEGKVEEAQGMMKLVEQLK-EERELLRSTTSTIESF-AAQEKQMEVCEVCGAFLIVGDAQSRVDDHLMGKQHMGYAKI 223
yLuc7p   NLKHTAEERMKIQQ-----VTEELDVLDVRIGLMGQEIDSLIRADEVSMGMLQSVKLQELISKRKEVAKRVRNITENVGQSAQQKLQVCEVCGAYLSRLDTDRRLADHFLGKIHLGYVKM 232
.*  : ::             : :. *  .*.    : : *   .:*. .      :::   .. :      .         ::::.*****.*:*   * : *: **: ** *:*:  :
xLuc7A   REKLEMLRRTVAE-KQEKRNQDRLKRREEREKDDR-TGRRSKSKSRDRRRSRSKERRRRRSQSSSRDRRR-SRSRSR-------------DRHRRHRSRSGSRNRS--HHQS-------- 315
xLuc7B   REKLELLRRTVAE-KQEKRNQDRLKRREERERDDH-LGRRSKSKSKDRRRSRSKERRRRRSQSSSHDRRR-SRSRSR-------------DRHRRHRSRSGSRNRS--HYRS-------- 315
hLuc7B1  REKLDQLRKTVAE-KQEKRNQDRLRRREEREREER-LSRRSGSRTRDRRRSRSRDRRRRRSRSTSRERRKLSRSRSR-------------DRHRRHRSRSRSHSRG--HRRA-------- 316
hLuc7B2  REKLEELKRVVAE-KQEKRNQERLKRREEREREEREKLRRSRSHSKNPKRSRSREHRRHRSRSMSRERKRRTRSKSR-------------EKRHRHRSRSSSRSRSRSHQRSRHS----- 322
xLuc7C   REKLDELKRLVAE-KQEKRNQDRLKRREERDREEREKLK---------KRSRSREKRRHRSRSSSRDRKRRTRSKSR-------------EKRHRHRSRSGSRSRSHSHQRS-------- 310
dLuc7    REKLIELEKTAAPRKAELKRTGKMTDREDEGRGRNRYFVGGRELDRRSRVHRSRSRERQRNRDGDRERPNNGRGPEEKGSERPKEAADGPERAERAPDRGGRRDDRDNHGRDHRERERDG 346
hLuc7A   KATVEELKEKLRKRTEEPDRDERLK-KEKQEREER-EKEREREREERERKRRREEEEREKERARDRERRKRSRSRSRHSSRTSDRRCSRSRDHKRSRSRERRRSRSRDRRRSRSHD-RSE 340
yLuc7p   REDYDRLMKNNRTTNASKTATTLPGRRFV-------------------------------
:     * .     . .         :                            
xLuc7A   --SRDRGSKHK---------------------------------------------------------------------------------
xLuc7B   --SRDRGSKHK---------------------------------------------------------------------------------
hLuc7B1  --SRDRSAKYKF----------------SRERASREESWESGRSERGPPDWRLESSNGKMASRRSEEKEAGEI------------------- 371
hLuc7B2  --SRDRSRERSKRRSSKERFRDQDLASCDRDRSSRDRSPRDRDRKDKKRSY-ESANGRSEDRRSSEEREAGEI------------------- 392
xLuc7C   ---RDRSR----------------------DRSSRTK-------------------------------------------------------
dLuc7    RRDRDRHGRNDRGRFGDRGGGGGGGGHHRDDRRRSRSRERSPRERRNFNHFRDGGGGGNGQRKRSYSRERNYRR------------------ 420
hLuc7A   RKHRSRSRDRRRSKSRDRKSYKHRSKSRDREQDRKSKEKEKRGSDDKKSSVKSGSREKQSEDTNTESKESDTKNEVNGTSEDIKSEGDTQSN 432
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Figure 5. Metazoan Luc7 proteins. (A) Alignment of the yeast, Xenopus, Drosophila and human Luc7 proteins. The multiple sequence alignment
of yLuc7p and the two human proteins deduced from the cDNA sequences underlines the two conserved zinc ﬁnger motifs and the human-speciﬁc
C-terminal extensions with sequence composition typical of a splicing factor. (B) Structure of the hLuc7A gene showing the diﬀerent alternative
splice site variants. (C) Western blot with anti-hLuc7A antibodies in cell extracts from several cell types. Thirty micrograms of protein extract were
loaded in each lane.
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U1 snRNA
In yeast, yLuc7p is tightly associated to the U1 snRNP.
This allowed puriﬁcation of U1 snRNP by using a tagged
version of yLuc7p (18). Puriﬁed human U1 snRNP
contains only three speciﬁc proteins U1-A, U1-C and
U1-70k (34). However it is possible that some other
proteins interacting loosely and/or non-stoichiometrically
with the U1 snRNP are not detected after the puriﬁcation
process. In order to know whether hLuc7A associates
to U1 snRNP, we performed immunoprecipitation of
HeLa nuclear extracts with antibodies against hLuc7A
and assayed for the presence of U1 snRNA in the pellets.
As positive control we used antibodies against the U1
snRNP protein, U1-A. As negative control an antibody
that recognizes POP1, an RNase MRP component, was
used. U1-A antibodies precipitated U1 snRNA (Figure 7,
lane 11). However, only background is seen with POP1
antibodies (Figure 7, lane 10). Antibodies raised against
the N-terminal or the C-terminal regions of hLuc7A
speciﬁcally precipitated a signiﬁcant amount of U1
snRNA but not U2 snRNA (Figure 7, lanes 7 and 8).
The pre-immune serum precipitated only background
levels of U1 snRNA (Figure 7, lane 9). Analysis of the
supernatant conﬁrmed that lack of co-precipitation did
not result from RNA degradation (lanes 2–6) Western
blot analysis also demonstrated that anti-hLuc7p
antibodies co-precipitated speciﬁcally the U1-A protein
(data not shown). These results show that hLuc7A
associates speciﬁcally to U1 snRNP despite the fact that
it does not copurify with it.
hLuc7A affects 50 splicesite selection in vivo
hLuc7A can be depleted to 97% from HeLa nuclear
extracts by using a mixture of antibodies generated against
it. These extracts, when assayed in splicing in vitro by
using several reporters (35) are 2- to 3-fold less active (data
not shown). To further demonstrate a role for hLuc7A in
pre-mRNA splicing, we decided to analyze the eﬀect of
overexpression of hLuc7A on splicing of a reporter in vivo.
We used the system where HeLa cells are co-transfected
with an adenovirus E1A reporter and overexpress SF2,
which activates splicing from proximal (13s) sites
(Figure 8B) (25,27). We then analyzed the eﬀect of
co-transfected hLuc7A on splicing. As a positive
control we co-transfected hnRNPA1, which activates
distal sites (9s) and counteracts the eﬀect of SF2.
Figure 8A and D, lane 1, shows the pattern of mRNAs
obtained when E1A reporter is transfected with SF2
alone. The 13s, 12s and 9s mRNAs derived from splicing
are shown. Co-transfection of hnRNPA1 activated spli-
cing from the distal site detected as a reduction in 13s and
a relative increase in 9s (compare Figure 8A and D, lanes
1–3). hLuc7A overexpression acted in a similar way to
hnRNPA1, by preventing reproducibly the splicing from
the proximal sites (12s and 13s). Therefore overexpression
of hLuc7A switched 50 splice site utilization towards the
more distal site, an eﬀect similar to that produced by
hnRNPA1. Taken together, our results demonstrate that
hLuc7A is a new splicing factor.
DISCUSSION
Our work provides insight in the role of yLuc7p in
splicing, which we ﬁnd remarkably similar to that
of Nam8p. We previously showed (13) that Nam8p, a
U1 snRNP component, binds the pre-mRNA during
commitment complex formation in a region directly
Anti-hLuc7A Anti-tubulin DAPI
Figure 6. hLuc7A is a nuclear protein. In situ staining was performed in HeLa cells with antibodies against hLuc7A (green) and tubulin (red).
DAPI appears in blue.
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Figure 7. hLuc7A is associated to U1 snRNA. Immunoprecipitation
experiments were performed with HeLa nuclear extracts and diﬀerent
sera. Lane 1, input, lanes 2–6 supernatants, lanes 7–11 pellets.
Antibodies recognized: h-Luc7A N-terminal region (lanes 2 and 7)
and C-terminal region (lanes 3 and 8); POP1 (lanes 5 and 10); U1-A
(lanes 6 and 11). Lanes 4 and 9, pre-immune serum corresponding to
C-terminal antibody.
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Figure 8. hLuc7A aﬀects splicing in vivo.( A) A representative image of splicing analysis carried out in HeLa cells co-transfected with E1A reporter
plasmid and expression plasmids for SF2, hnRNPA1 and hLuc7A. After transfection, total RNA was puriﬁed and radioactive RT–PCR was
performed using primers speciﬁc for the exons. HeLa cells were transfected with 300ng of E1A reporter and 170ng of SF2 expression plasmid
(lanes 1–5). In addition, 90 or 130ng of hnRNPA1 (lanes 2 and 3) or hLuc7A (lanes 4 and 5) were co-transfected. The splicing products
corresponding to the 13s, 12s and 9s forms are indicated. pBluescript was used to normalize the amount of DNA. We cloned and sequenced the band
migrating just above the 9s splicing product and it contains a modiﬁed duplication of the 9s sequence, suggesting that it corresponds to a PCR
artifact derived from primer–dimer pairing on the 9s splicing product. Its intensity correlates with the intensity of the 9s band (data not shown).
(B) Schematic diagram representing the E1A reporter with the diﬀerent splicing products (13s, 12s and 9s). The primers used for analysis of splicing
activity by RT–PCR are marked with two arrows. (C) Western blot of the expressed proteins from panel A using the T7 epitope tag. Two diﬀerent
exposures are shown (above and below). Bands corresponding to SF2, hnRNPA1 and hLuc7A are indicated. (D) Quantiﬁcation of data presented in
panel A. The intensity of bands corresponding to 13s, 12s and 9s mRNAs from three independent experiments was quantiﬁed with a phosphorimager
and represented as percentage for each form,  SD.
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mRNA–U1 snRNP interaction and helps in the formation
of commitment complexes. We also showed that
changes in the pre-mRNA sequence introduced in the
non-conserved region contacted by Nam8p produced a
striking Nam8p-dependent eﬀect in splice site recognition
and selection. Thus, Nam8p by stabilizing U1 snRNP–pre-
mRNA interaction modulates splicing (13). We now
propose that yLuc7p acts in a similar way. yLuc7p contacts
non-conserved sequences in the exon, and in the speciﬁc
context of our synthetic constructs, in a region within 23nt
from the cap. We also showed that this contact occurs
mainly through its ﬁrst zinc ﬁnger. Interestingly, similarly
to what happens with Nam8p, changes in the non-
conserved pre-mRNA sequence bound by yLuc7p aﬀect
splice site selection, and this eﬀect is dependent on the
presence of its ﬁrst zinc ﬁnger too. Fortes et al. (17) showed
that extracts from yLuc7p mutant strains display defects in
all steps of splicing in vitro, andthese defects can be rescued
by adding recombinant yLuc7p. They also showed that
yLuc7p mutants exhibit reduced splicing activity in vivo,
and that yLuc7p is required for CBC–U1snRNP interac-
tions. Based on our data, and in agreement with the data
from Fortes et al (17), we propose a model where yLuc7p
contacts the pre-mRNA in a region close to the cap, where
it is more likely to establish an interaction with CBC.
yLuc7p acts by binding the pre-mRNA upstream the 50
splice site and stabilizing pre-mRNA–U1 snRNP interac-
tion in commitment complexes. Therefore, yLuc7p could
directly or indirectly interact with CBC and mediate the
CBC eﬀect in splice site selection. Zhang and Rosbash (14)
showed that another U1snRNP component, U1-C, con-
tacts the pre-mRNA and stabilizes its interaction with the
U1snRNA. Altogether, yLuc7p, U1-C, Nam8p, CBC and
maybeother U1 snRNP proteins (ySnp1p/U1-70K, SmD1,
SmD3 and Snu56p) (14) would interact with the
pre-mRNA and produce a network of protein–RNA
interactions keeping the pre-mRNA stably bound to the
U1 snRNP.
yLuc7p has two zinc ﬁnger motifs. We show that the
ﬁrst one cross-links the pre-mRNA and it is required for
yLuc7p splicing activity. What is then the role for the
second zinc ﬁnger? The U1 snRNP particle puriﬁed from a
yLuc7p mutant strain appears completely disrupted,
missing several proteins and it is inactive in splicing (17).
It is possible that yLuc7p acts as a bridge between the
pre-mRNA and the U1 snRNA through its two zinc
ﬁngers, the ﬁrst one binding to the pre-mRNA and the
second one binding to U1 snRNA. We tried to generate a
yeast strain lacking the second zinc ﬁnger but we did not
succeed. Diploid cells integrated the mutation but after
sporulation none of the spores harboring the deletion were
viable. This indicates that the integrity of the second zinc
ﬁnger is necessary for viability. Perhaps it is required
to keep a minimal structure of the U1 snRNP. It is also
possible that the second zinc ﬁnger contributes to stabilize
globally the snRNP–pre-mRNA interaction by coopera-
tively helping the ﬁrst zinc ﬁnger bind the pre-mRNA.
Further experiments will be necessary to clarify this point.
Three U1 speciﬁc proteins co-purify with human U1
snRNP (U1-A, U1-C and U1-70k) and all three have
counterparts in yeast U1 snRNP. In contrast, yeast U1
snRNP has seven additional proteins (Snu71p, Snu65p,
Snu56p, Prp39p, Prp40p, Nam8p and yLuc7p).
However, a human homolog has been described only for
Nam8p, the apoptotic factor TIA-1 (19). Here we
demonstrate that hLuc7A is a new splicing factor,
homolog to yeast yLuc7p. Human hLuc7A is a nuclear
protein expressed in several human cell lines (Figures 5
and 6). Importantly, antibodies against hLuc7A speciﬁ-
cally precipitate U1 snRNA (Figure 7), indicating that it is
a bona ﬁde U1snRNP component. Interestingly, hLuc7A
aﬀects splice site selection by activating splicing from
the distal 50 splice site (Figure 8). Supporting our results,
a recent report identiﬁed the new SR protein, SRrp53,
as a protein interacting with hLuc7A (36). In addition,
hLuc7A was puriﬁed with the supraspliceosome, a
macromolecular complex involved in pre-mRNA splicing
(37). Therefore, we conclude that hLuc7A is a new splicing
factor.
hLuc7 has three isoforms (hLuc7A, hLuc7B1 and
hLucB2) derived from diﬀerent genes, suggesting that it
could be tissue speciﬁc or developmentally regulated. ESTs
analysis shows that the pre-mRNA for hLuc7A undergoes
alternative splicing, although we do not know yet the
biological meaning of this variability. It is possible that
hLuc7B1 and hLuc7B2 are also regulated by alternative
splicing. The abundance of isoforms present in mammalian
cells is remarkable when compared to the simplicity of the
yeast system. This underscores the degree of complexity in
the regulation of splicing in mammalian systems.
hLuc7A has a C-terminal tail rich in Asp, Ser and Arg
repeats. These repeats are present in the splicing factors
known as SR proteins where they have been shown to
act as protein–protein interaction modules, or to
inﬂuence RNA–RNA interactions. The SR repeats in
hLuc7A could act by recruiting other splicing factors to
the pre-mRNA, or by stabilizing U1snRNP–pre-mRNA
interactions. The fact that hLuc7A does not co-purify
with human U1 snRNP (38) indicates that it remains
loosely associated to this particle. This situation
allows for more ﬂexibility in the regulation of splice
site selection. Thus, hLuc7A could ﬁrst bind the
pre-mRNA independently from U1 snRNP and, perhaps
through interaction with U1-70k (via their RS domains)
or by direct binding to U1 snRNA, could subsequently
recruit the U1 snRNP to form the E-complex. In this
sense, hLuc7A would act in a similar way than TIA-1,
the human homolog of yeast Nam8p (19). Interestingly,
human and yeast Luc7p share 50% identity in the zinc
ﬁnger region suggesting that the mechanism of action
might be similar. More experiments will be necessary to
conﬁrm this hypothesis.
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